CY2021036I1 - Αντισωματα anti-angptl3 και χρησεις αυτων - Google Patents

Αντισωματα anti-angptl3 και χρησεις αυτων

Info

Publication number
CY2021036I1
CY2021036I1 CY2021036C CY2021036C CY2021036I1 CY 2021036 I1 CY2021036 I1 CY 2021036I1 CY 2021036 C CY2021036 C CY 2021036C CY 2021036 C CY2021036 C CY 2021036C CY 2021036 I1 CY2021036 I1 CY 2021036I1
Authority
CY
Cyprus
Prior art keywords
angptl3 antibodies
angptl3
antibodies
Prior art date
Application number
CY2021036C
Other languages
English (en)
Other versions
CY2021036I2 (el
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2021036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY2021036I1 publication Critical patent/CY2021036I1/el
Publication of CY2021036I2 publication Critical patent/CY2021036I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY2021036C 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων CY2021036I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498518P 2011-06-17 2011-06-17
US201161578309P 2011-12-21 2011-12-21

Publications (2)

Publication Number Publication Date
CY2021036I1 true CY2021036I1 (el) 2022-03-24
CY2021036I2 CY2021036I2 (el) 2022-05-27

Family

ID=46298728

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων
CY2021036C CY2021036I2 (el) 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων

Country Status (46)

Country Link
US (7) US9018356B2 (el)
EP (2) EP3418301A1 (el)
JP (2) JP6400471B2 (el)
KR (1) KR102031007B1 (el)
CN (1) CN103732624B (el)
AR (1) AR087329A1 (el)
AU (1) AU2012271663B2 (el)
CA (1) CA2838867C (el)
CL (1) CL2013003552A1 (el)
CO (1) CO6821892A2 (el)
CR (1) CR20130621A (el)
CY (2) CY1120996T1 (el)
DK (1) DK2721065T3 (el)
DO (1) DOP2013000299A (el)
EC (1) ECSP13013085A (el)
ES (1) ES2699499T3 (el)
FI (1) FIC20210028I1 (el)
FR (1) FR21C1061I2 (el)
GT (1) GT201300306A (el)
HR (1) HRP20182098T1 (el)
HU (1) HUS2100034I1 (el)
IL (2) IL229612B (el)
JO (1) JO3412B1 (el)
LT (2) LT2721065T (el)
LU (1) LUC00231I2 (el)
MA (1) MA35190B1 (el)
MX (2) MX337644B (el)
MY (1) MY160516A (el)
NI (1) NI201300136A (el)
NL (1) NL301122I2 (el)
NO (2) NO2021037I1 (el)
PE (1) PE20141166A1 (el)
PH (1) PH12013502570B1 (el)
PL (1) PL2721065T3 (el)
PT (1) PT2721065T (el)
RS (1) RS58310B1 (el)
RU (1) RU2620064C2 (el)
SG (1) SG195165A1 (el)
SI (1) SI2721065T1 (el)
SM (1) SMT201800658T1 (el)
TR (1) TR201816591T4 (el)
TW (3) TW201920261A (el)
UA (1) UA114891C2 (el)
UY (2) UY39340A (el)
WO (1) WO2012174178A1 (el)
ZA (1) ZA201308879B (el)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
US20170233466A1 (en) 2016-02-17 2017-08-17 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Atherosclerosis by Administering an Inhibitor of ANGPTL3
CA3016764A1 (en) * 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
AU2017248356A1 (en) 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor
HUE071912T2 (hu) * 2016-04-28 2025-10-28 Regeneron Pharma Eljárások örökletes hiperkoleszterinémiában szenvendõ betegek kezelésére
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CA3084059A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
US20190234959A1 (en) 2018-01-31 2019-08-01 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
EP3759242A1 (en) 2018-02-28 2021-01-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
KR102503356B1 (ko) 2018-03-19 2023-02-24 리제너론 파마슈티칼스 인코포레이티드 마이크로칩 모세관 전기영동 분석 및 시약
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
MX2021002281A (es) 2018-08-30 2021-05-27 Regeneron Pharma Metodos para caracterizar complejos proteicos.
US20220025344A1 (en) * 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
MY202602A (en) 2019-01-16 2024-05-09 Regeneron Pharma Methods for identifying free thiols in proteins
WO2020185952A1 (en) * 2019-03-11 2020-09-17 xCella Biosciences, Inc. Cd27-binding antibodies and uses thereof
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
MX2022000094A (es) * 2019-07-04 2022-04-27 Cadila Healthcare Ltd Vacuna a base de angptl3 para el tratamiento de enfermedad hepática.
KR20220066393A (ko) 2019-09-24 2022-05-24 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2020394428B2 (en) 2019-11-25 2025-11-20 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
BR112022014306A2 (pt) * 2020-01-22 2022-09-20 Jiangsu Hengrui Medicine Co Anticorpo anti-angptl3 e uso do mesmo
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
EP4281542A1 (en) 2021-01-20 2023-11-29 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
BR112023017442A2 (pt) 2021-03-03 2023-09-26 Regeneron Pharma Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
US20240141029A1 (en) * 2021-03-05 2024-05-02 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
US20240092884A1 (en) * 2021-03-30 2024-03-21 Children's Hospital Of Fudan University Anti-angptl3 antibody or antigen-binding fragment thereof, and preparation method and use thereof
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
US20240352113A1 (en) * 2021-07-21 2024-10-24 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
US20230090912A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
IL312372A (en) 2021-10-26 2024-06-01 Regeneron Pharma Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
JP2025500414A (ja) * 2021-12-22 2025-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様３（ａｎｇｐｔｌ３）阻害剤による腎疾患の治療
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
KR102757647B1 (ko) 2022-05-02 2025-01-22 노보 노르디스크 에이/에스 고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白
CN116143919B (zh) * 2022-11-01 2025-06-13 中国药科大学 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
US20240198253A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
TWI288000B (en) 2001-02-22 2007-10-11 Rtp Pharma Inc Fibrate-statin combinations with reduced fed-fasted effects
KR101012904B1 (ko) * 2001-11-16 2011-02-08 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는조성물 및 이를 사용하는 방법
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
BRPI0712224B8 (pt) 2006-06-02 2021-05-25 Regeneron Pharma anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas
PT2069403E (pt) * 2006-10-02 2014-07-18 Regeneron Pharma Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
DK2121751T3 (en) * 2006-12-08 2017-04-24 Lexicon Pharmaceuticals Inc Monoclonal antibodies to ANGPTL3
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
ES2541217T3 (es) 2009-07-14 2015-07-16 The Scripps Research Institute Diferenciación de células madre mesenquimales
ES2677969T3 (es) 2010-01-08 2018-08-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión tipo angiopoyetina 3
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN112961855B (zh) * 2011-06-21 2024-08-09 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
BR112016013473A2 (pt) 2013-12-24 2017-10-03 Ionis Pharmaceuticals Inc Modulação da expressão de angiopoietina-tipo 3
EP3137605B1 (en) 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
MX379286B (es) 2014-07-16 2025-03-10 Sanofi Biotechnology INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
US20170233466A1 (en) 2016-02-17 2017-08-17 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Atherosclerosis by Administering an Inhibitor of ANGPTL3
CA3016764A1 (en) 2016-03-03 2017-09-08 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
AU2017248356A1 (en) 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor
HUE071912T2 (hu) 2016-04-28 2025-10-28 Regeneron Pharma Eljárások örökletes hiperkoleszterinémiában szenvendõ betegek kezelésére
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies

Also Published As

Publication number Publication date
PE20141166A1 (es) 2014-09-16
WO2012174178A1 (en) 2012-12-20
TWI644922B (zh) 2018-12-21
EP2721065A1 (en) 2014-04-23
US9018356B2 (en) 2015-04-28
JP2018166516A (ja) 2018-11-01
HRP20182098T1 (hr) 2019-02-08
RU2013155906A (ru) 2015-07-27
IL229612B (en) 2019-06-30
US20250136675A1 (en) 2025-05-01
IL229612A0 (en) 2014-01-30
AR087329A1 (es) 2014-03-19
PH12013502570B1 (en) 2019-01-16
US20190315851A1 (en) 2019-10-17
MX337644B (es) 2016-03-14
JP6400471B2 (ja) 2018-10-03
EP3418301A1 (en) 2018-12-26
FIC20210028I1 (fi) 2021-09-09
LTPA2021009I1 (el) 2021-09-27
KR20140037218A (ko) 2014-03-26
US20130171149A1 (en) 2013-07-04
CY1120996T1 (el) 2019-12-11
FR21C1061I2 (fr) 2022-11-18
EP2721065B1 (en) 2018-09-12
TW201313738A (zh) 2013-04-01
RS58310B1 (sr) 2019-03-29
US20190092845A1 (en) 2019-03-28
RU2620064C2 (ru) 2017-05-22
TW201920261A (zh) 2019-06-01
MA35190B1 (fr) 2014-06-02
US20150197564A1 (en) 2015-07-16
MX2013014345A (es) 2014-01-31
US20220403016A1 (en) 2022-12-22
MY160516A (en) 2017-03-15
GT201300306A (es) 2015-03-09
CN103732624A (zh) 2014-04-16
HUS2100034I1 (hu) 2021-10-28
CR20130621A (es) 2014-02-12
CY2021036I2 (el) 2022-05-27
IL259436A (en) 2018-07-31
CN103732624B (zh) 2016-08-17
KR102031007B1 (ko) 2019-11-08
LUC00231I2 (el) 2025-02-03
NO2021037I1 (no) 2021-09-15
ZA201308879B (en) 2014-07-30
DOP2013000299A (es) 2014-04-15
CA2838867C (en) 2020-07-14
TR201816591T4 (tr) 2018-11-21
US10358487B2 (en) 2019-07-23
NZ619092A (en) 2016-03-31
PL2721065T3 (pl) 2019-02-28
PH12013502570A1 (en) 2014-01-27
JP2014523739A (ja) 2014-09-18
NI201300136A (es) 2014-05-15
UA114891C2 (uk) 2017-08-28
MX361859B (es) 2018-12-18
AU2012271663A1 (en) 2014-01-16
LT2721065T (lt) 2018-12-10
CL2013003552A1 (es) 2014-07-25
UY34137A (es) 2013-01-03
NL301122I1 (el) 2021-09-01
FR21C1061I1 (fr) 2022-01-21
US20220153825A1 (en) 2022-05-19
JO3412B1 (ar) 2019-10-20
TW201815822A (zh) 2018-05-01
NL301122I2 (nl) 2021-12-30
CO6821892A2 (es) 2013-12-31
CA2838867A1 (en) 2012-12-20
US9951127B2 (en) 2018-04-24
SI2721065T1 (sl) 2018-12-31
SMT201800658T1 (it) 2019-01-11
AU2012271663B2 (en) 2017-04-20
LTC2721065I2 (el) 2022-10-25
PT2721065T (pt) 2018-12-06
UY39340A (es) 2021-08-31
ES2699499T3 (es) 2019-02-11
NO2025028I1 (no) 2025-06-13
DK2721065T3 (en) 2018-12-03
ECSP13013085A (es) 2014-01-31
SG195165A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
CY2021036I2 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
CY2020045I1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2022019I1 (el) Συνθεσεις αντι-cgrp και χρησεις αυτων
CY2024022I1 (el) Αντιμυκητιασικοι παραγοντες και χρησεις αυτων
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL231777A0 (en) Antibodies against tl1a and uses thereof
IL249650A0 (en) Antibodies directed against icos and uses thereof
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
CO6811812A2 (es) Anticuerpo anti-b7-h3
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
BR112012030311A2 (pt) anticorpo
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
CR20140127A (es) Anticuerpo anti-abtcr
BR112014009050A2 (pt) pirrolbenzodiazepinas e conjugados destas
HUE056313T2 (hu) Anti-DLL3 antitest
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
BR112014028457A2 (pt) anticorpos anti-fcrn
EP3546481C0 (en) ANTI-INTERLEUKIN 22 ANTIBODIES (IL-22) AND THEIR USES
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
CO6791565A2 (es) Anticuerpos anti-notch1